XLS.SW Xlife Sciences AG

Healthcare Biotechnology SIX Swiss Exchange
8.42 CHF
Close of Nov 7, 2026
8.22 26.80
Market cap
CHF 48.6M
P/E
-
P/B
0.42x
ROE
-7.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is XLS.SW undervalued?

Graham number

The Graham number of Xlife Sciences AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Xlife Sciences AG fundamental analysis

No fundamental analysis for Xlife Sciences AG yet.

Xlife Sciences AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Xlife Sciences AG

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services. It also develops novel treatment options in specific indica…

Full company profile